No. | U.S. and European Patents and Patent Applications by MVP Scientists |
1 | Williams LD, Hershfield M, Kelly SJ, Saifer MGP, Sherman MR (2018) PEG-urate oxidase conjugates and use thereof. U.S. Patent No. 9,885,024 B2 |
2 | Williams LD, Hershfield MS, Kelly SJ, Saifer MGP, Sherman MR (2017) Isolated Tetrameric Uricase. European Patent Specification EP 2 316 475 B1; validated in 19 countries. |
3 |
Martinez AL, Sherman MR. Saifer MGP, Williams LD (2017) Polymer conjugates with decreased antigenicity, methods of
preparation and uses thereof. US Patent Application 2017/0189544 A1 For license opportunity, contact busdev@mvpharm.com. |
4 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2016) PEG-urate
oxidase conjugates and use thereof. US Patent Application 2016/0160188 A1 |
5 | Saifer
MGP, Martinez AL, Williams LD, Sherman
MR (2015) Polymer conjugates of interferon-beta with enhanced biological
potency. U.S. Patent No. 9,125,880 B2. For license opportunity, contact busdev@mvpharm.com |
6 |
Sherman MR, Saifer
MGP, Williams LD, Hershfield MS, Kelly SJ (2014) Aggregate-free
urate oxidase for preparation of non-immunogenic polymer conjugates. US Patent Application 2014/0363414 A1 |
7 |
Sherman MR, Saifer MGP,
Williams LD, Hershfield MS, Kelly SJ (2014) Conjugates
prepared with aggregate-free proteins. European Patent Specification EP 2 305 819 B1; validated in 20 countries. |
8 | Sherman MR, Saifer MGP, Williams LD, Hershfield MS, Kelly SJ (2014) Method for purifying urate oxidase tetramers and octamers. US Patent 8,921,064 B2 |
9 | Sherman MR, Saifer MGP,
Williams LD, Hershfield MS, Kelly SJ (2014) Conjugates prepared with
aggregate-free proteins. European Patent Specification EP 2 196 538 B1; validated in 12 countries. For license opportunity, contact busdev@mvpharm.com. |
10 | Martinez AL,
Sherman MR, Saifer MGP,
Williams LD (2014) Polymer conjugates with decreased
antigenicity, methods of preparation and uses thereof. European Patent Specification EP 1 572 728 B1; validated in 22 countries. For license opportunity, contact busdev@mvpharm.com. |
11 |
Williams LD, Hershfield M, Kelly SJ, Saifer MGP,
Sherman MR (2013) PEG-urate oxidase conjugates and use
thereof. US Patent 8,618,267 B2 |
12 | Williams LD, Hershfield MS, Kelly SJ,
Saifer MGP, Sherman MR (2013) PEG-urate oxidase conjugates and use
thereof. European Patent Specification EP 2 158 923 B1; validated in 19 countries. |
13 | Williams LD, Hershfield M, Kelly SJ, Saifer MGP, Sherman
MR (2013) PEG-urate oxidase conjugates and use
thereof. US Patent Application 2013/0052677 A1 |
14 | Saifer MGP, Martinez AL,
Williams LD, Sherman MR (2012) Polyethylene glycol conjugates of
interferon-beta-1b with enhanced in vitro biological potency.
European Patent Specification EP 1 667 708 B9; validated in 22 countries. For license opportunity, contact busdev@mvpharm.com. |
15 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2012) PEG-urate
oxidase conjugates and use thereof. US Patent Application 2012/0149083 A1 |
16 | Martinez AL, Sherman
MR, Saifer MGP, Williams LD (2012) Polymer conjugates with
decreased antigenicity, methods of preparation and uses thereof. US Patent Application 2012/0114742 A1 For license opportunity, contact busdev@mvpharm.com. |
17 | Martinez AL, Sherman MR, Saifer MGP,
Williams LD (2012) Polymer
conjugates with decreased antigenicity, methods of preparation and uses
thereof. US Patent 8,129,330 B2 For license opportunity, contact busdev@mvpharm.com. |
18 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2011) PEG-urate
oxidase conjugates and use thereof. US Patent 8,067,553 B2 |
19 | Sherman MR, Saifer MGP,
Williams LD, Hershfield MS, Kelly SJ (2011) Aggregate-free urate
oxidase for preparation of non-immunogenic polymer conjugates. US Patent Application 2011/0287466 A1 |
20 | Sherman MR, Saifer MGP,
Williams LD, Hershfield MS, Kelly SJ (2011) Aggregate-free urate
oxidase for preparation of non-immunogenic polymer conjugates. US Patent 7,927,852 B2 |
21 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2011) PEG-urate oxidase conjugates
and use thereof. US Patent 7,927,589 B2 |
22 |
Williams LD, Hershfield MS, Kelly SJ, Saifer MGP, Sherman MR (2011) PEG-urate
oxidase conjugates and use thereof. European Patent Specification EP 1 588 716 B1; validated in 19 countries. |
23 | Sherman MR, Saifer MGP,
Williams LD, Hershfield MS, Kelly SJ (2010) Aggregate-free urate
oxidase for preparation of non-immunogenic polymer conjugates. European Patent Specification EP 1 254 237 B1; validated in 20 countries. |
24 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2010) PEG-urate oxidase conjugates and use thereof.
US Patent Application 2010/323423 A1 |
25 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2010) PEG-urate oxidase conjugates and use thereof.
US Patent Application 2010/323422 A1 |
26 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2010) PEG-urate oxidase conjugates and use thereof.
US Patent 7,723,089 B2 |
27 | Sherman MR, Martinez AL, Bhaskaran SS,
Williams LD, Saifer MGS, French JA (2008) Polymer stabilized proteinases. European Patent Specification EP 1 421 175 B1; validated in 10 countries. For license opportunity, contact busdev@mvpharm.com. |
28 | Bhaskaran SS, Sherman MR,
Saifer MGP, Williams LD (2008)
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity.
US Patent Application 2008/00058246 A1 For license opportunity, contact busdev@mvpharm.com. |
29 | Sherman MR, Saifer MGP,
Williams LD, Hershfield MS, Kelly SJ (2008) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates.
US Patent Application 2008/0057048 A1 |
30 | Williams LD, Hershfield MS, Kelly SJ,
Saifer MGP, Sherman MR (2008) PEG-urate oxidase conjugates and use thereof.
US Patent Application 2008/0031864 A1 |
31 | Sherman MR, Martinez AL,
Bhaskaran SS, Williams LD, Saifer MGS,
French JA (2007) Polymer conjugates of proteinases.
US Patent 7,229,810 B2 For license opportunity, contact busdev@mvpharm.com. |
32 | Williams LD, Hershfield MS, Kelly SJ,
Saifer MGP, Sherman MR (2005) PEG-urate oxidase conjugates and use thereof.
European Patent Specification EP 1 100 542 B1; validated in 19 countries |
33 | Sherman MR, Saifer MGP,
Williams LD (2005) Aggregate-free protein compositions and methods of preparing same.
US Patent Application 2005/0014240 A1 For license opportunity, contact busdev@mvpharm.com. |
34 | Sherman MR, Saifer MGP,
Williams LD
(2004) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates.
US Patent 6,783,965 B1 |
35 | Bhaskaran SS, Sherman MR,
Saifer MGP, Williams LD (2004) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity.
PCT Publication WO 2004/060300 A2; granted or validated in 17 countries. For license opportunity, contact busdev@mvpharm.com. |
36 | Saifer MGP, Martinez AL,
Williams LD, Sherman MR (2004) Polymer conjugates of interferon-beta with enhanced biological potency.
PCT Publication WO 2004/060299 A2; granted or validated in 43 countries. For license opportunity, contact busdev@mvpharm.com. |
37 | Bhaskaran SS, Sherman MR,
Saifer MGP, Williams LD (2004) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity.
US Patent Application 2004/0136952 A1 |
38 | Saifer MGP, Martinez AL,
Williams LD, Sherman MR, (2004) Polymer conjugates of interferon-beta with enhanced biological potency.
US Patent Application 2004/0126361 A1 For license opportunity, contact busdev@mvpharm.com. |
39 | Martinez AL, Sherman MR,
Saifer MGP, Williams LD (2004) Polymer conjugates with decreased antigenicity, methods of preparation and use.
US Patent Application 2004/0062746 A1; patent No. 8,129,330 granted (divisional application pending). For license opportunity, contact busdev@mvpharm.com. |
40 | Martinez AL, Sherman MR,
Saifer MGP, Williams LD (2004) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof.
PCT Publication WO 04/030617 A2; granted or validated in 51 countries. For license opportunity, contact busdev@mvpharm.com. |
41 | Saifer MGP, Williams LD (2004) Quantitative detection of viruses by light scattering.
European Patent Specification EP 1 218 722 B1; validated in three countries. For license opportunity, contact busdev@mvpharm.com. |
42 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2003) PEG-urate oxidase conjugates and use thereof.
US Patent Application 2003/0166249 A1 |
43 | Williams LD, Hershfield M, Kelly SJ,
Saifer MGP, Sherman MR (2003) PEG-urate oxidase conjugates and use thereof.
US Patent 6,576,235 B1 |
44 | Sherman MR, Martinez AL, Bhaskaran SS,
Williams LD, Saifer MGP, French JA (2003) Polymer conjugates of proteinases.
US Patent Application 2003/0012777 A1; patent No.7,229,810 granted. For license opportunity, contact busdev@mvpharm.com. |
45 | Sherman MR, Martinez AL,
Bhaskaran SS, Williams LD, Saifer MGP (2003) Polymer stabilized proteinases.
PCT Publication WO 03/002716 A2; granted in U.S. and Europe. For license opportunity, contact busdev@mvpharm.com. |
46 | Saifer MGP, Williams LD (2003) Quantitation of viruses by light scattering.
US Patent 6,544,770 B2 For license opportunity, contact busdev@mvpharm.com. |
47 | Saifer MGP, Williams LD (2002) Quantitation of viruses by light scattering.
US Patent Application 2002/0028439 A1 |
48 | Sherman MR, Saifer MGP,
Williams LD (2001) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates.
PCT Publication WO 01/59078 A2; 70 patents granted in 38 countries. |
49 | Saifer MGP, Williams LD (2001) Quantitation of viruses by light scattering.
US Patent 6,316,185 B1 For license opportunity, contact busdev@mvpharm.com. |
50 | Saifer MGP, Williams LD (2001) Quantitative detection of viruses by light scattering.
PCT Publication WO 01/38852 A1; granted in U.S., Europe and Canada. For license opportunity, contact busdev@mvpharm.com. |
51 | Williams LD, Hershfield MS, Kelly SJ,
Saifer MGP, Sherman MR (2000) PEG-urate oxidase conjugates and use thereof.
PCT Publication WO 00/07629 A2; 97 patents granted in 38 countries. |
52 | Saifer M, Somack R, Williams LD (1995) Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols.
US Patent 5,468,478 (expired) |
53 | Saifer M, Somack R, Williams LD (1994) Intermediates for conjugation of polypeptides with high molecular weight polyalkylene glycols.
US Patent 5,283,317 (expired) |
54 | Saifer M, Somack R, Williams LD (1992) Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols.
US Patent 5,080,891 (expired) |
55 | Saifer M, Somack R, Williams LD (1991) Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols.
US Patent 5,006,333; issued in 24 additional countries. (all expired) |
56 | Huber W, Saifer MGP, Williams, LD (1978) N-Carbamylated orgotein.
US Patent 4,070,459; issued in seven additional countries. (all expired) |
57 | Huber W, Saifer MGP, Williams LD (1977) Alkylated orgotein.
US Patent 4,042,689; issued in seven additional countries. (all expired) |
58 | Huber W, Saifer MGP, Williams LD (1977) Esterified orgotein.
US Patent 4,022,888; issued in seven additional countries. (all expired) |
59 | Huber W, Saifer MGP, Williams LD (1977) Radioactive labeled orgotein.
US Patent 4,022,877; also issued in Canada. (both expired) |
60 | Saifer MGP, Williams LD,
Huber W (1977) Reduction of superoxide accumulation caused by smoke inhalation.
US Patent 4,022,224 (expired) |
61 | Huber W, Saifer MGP, Williams LD (1977) Acylated orgotein.
US Patent 4,017,605; issued in 14 additional countries. (all expired) |
62 | Huber W, Saifer MGP, Williams LD (1977) Cross-linked orgotein.
US Patent 4,009,267; issued in eight additional countries. (all expired) |
63 | Huber W, Chow S H, Saifer MGP (1974) Enzymatic treatment of protein mixtures containing orgotein. US Patent 3,806,411; issued in 25 additional countries. (all expired) |